Department of Systems Biology, University of Alcalá, Madrid, Spain; Department of Sport and Health, Spanish Agency for Health Protection in Sport (AEPSAD), Madrid, Spain.
Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.
J Physiother. 2020 Apr;66(2):89-96. doi: 10.1016/j.jphys.2020.03.006. Epub 2020 Apr 11.
Does neuromuscular electrical stimulation (NMES) applied during haemodialysis sessions improve functional capacity in people with end-stage renal disease? Does NMES used in this way also improve muscle strength, muscle mass/architecture, psychological outcomes, cardiovascular outcomes and biochemical variables? Does it have any adverse effects?
Systematic review of randomised controlled trials with meta-analysis. PubMed, Web of Science, Scopus and SPORTDiscus were searched from inception to 15 October 2019.
Patients receiving haemodialysis for end-stage renal disease.
NMES administered during haemodialysis sessions versus control.
Functional capacity, muscle strength, muscle mass, psychological outcomes, cardiovascular outcomes, biochemical variables and adverse events.
Data were meta-analysed where possible and results were expressed as the pooled mean difference between groups with a 95% confidence interval.
Eight studies (221 patients) were included in the analysis. Overall, the methodological quality of the studies was fair to good. NMES improved functional capacity as assessed by the 6-minute walk distance test (MD 31 m, 95% CI 13 to 49) and peak workload attained in incremental exercise (MD 12.5 W, 95% CI 3.2 to 21.9). NMES increased knee extensor muscle strength (MD 3.5 kg, 95% CI 2.3 to 4.7) and handgrip strength (MD 2.4 kg, 95% CI 0.4 to 4.4). Muscle mass/architecture was not substantially affected. NMES was estimated to be beneficial for several domains of quality of life in several studies, although most of these estimates were imprecise. No benefits were found for cardiovascular outcomes. The available data did not establish any clear effects on cardiovascular outcomes or biochemical variables (dialysis efficiency, urea and creatinine). No major NMES-related adverse events were observed.
NMES is safe, practical and effective for improving functional capacity and muscle strength in haemodialysis patients. Further research is needed to confirm the clinical relevance of these findings.
PROSPERO CRD42018107323.
在血液透析过程中应用神经肌肉电刺激(NMES)是否能改善终末期肾病患者的功能能力?这种方式的 NMES 是否还能改善肌肉力量、肌肉质量/结构、心理结果、心血管结果和生化变量?它有任何不良反应吗?
随机对照试验的系统评价和荟萃分析。从建库到 2019 年 10 月 15 日,在 PubMed、Web of Science、Scopus 和 SPORTDiscus 上进行了检索。
接受血液透析治疗终末期肾病的患者。
血液透析过程中 NMES 与对照组的比较。
功能能力、肌肉力量、肌肉质量、心理结果、心血管结果、生化变量和不良反应。
在可能的情况下进行了数据荟萃分析,结果表示为组间的汇总平均差异,置信区间为 95%。
有 8 项研究(221 名患者)纳入了分析。总体而言,研究的方法学质量为中等至良好。NMES 改善了 6 分钟步行距离测试(MD 31 m,95%CI 13 至 49)和递增运动中达到的峰值工作量(MD 12.5 W,95%CI 3.2 至 21.9)的功能能力。NMES 增加了膝关节伸肌肌力(MD 3.5 kg,95%CI 2.3 至 4.7)和握力(MD 2.4 kg,95%CI 0.4 至 4.4)。肌肉质量/结构没有受到实质性影响。在几项研究中,NMES 被估计对生活质量的几个领域有益,尽管这些估计大多数都不精确。没有发现对心血管结果有任何益处。目前的数据没有确定 NMES 对心血管结果或生化变量(透析效率、尿素和肌酐)有任何明确影响。没有观察到与 NMES 相关的重大不良反应。
NMES 安全、实用、有效,可改善血液透析患者的功能能力和肌肉力量。需要进一步的研究来证实这些发现的临床意义。
PROSPERO CRD42018107323。